Dotinurad

Products

We are here to help in anything you need. Please use our online system or send an email to .

Dotinurad

Inquiry

Catalog Number	PR1285572511
CAS	1285572-51-1
Description	Dotinurad is under investigation in clinical trial (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).
Synonyms	(3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2H)-yl)methanone
IUPAC Name	(3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone
Molecular Weight	358.2
Molecular Formula	C14H9Cl2NO4S
InChI	VOFLAIHEELWYGO-UHFFFAOYSA-N
InChI Key	InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2
Drug Categories	Antigout Preparations; Antirheumatic Agents; Heterocyclic Compounds, Fused-Ring; Thiazoles; Uricosuric Agents
Isomeric SMILES	C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
Type	Small Molecule
Therapeutic Category	Antigout Agent

Pharmacology

Mechanism of Action

Dotinurad operates by targeting and inhibiting the solute carrier family 22 member 12 (SLC22A12) protein in humans. This mechanism effectively reduces the reabsorption of uric acid in the kidneys, thereby promoting its excretion. The inhibition of SLC22A12, which is a known urate transporter, results in decreased serum uric acid levels, offering a therapeutic approach for managing conditions associated with hyperuricemia. This pharmacological action is central to Dotinurad's efficacy in mitigating elevated uric acid levels in patients.

It should be noted that our service is only used for research, not for clinical use.